Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
K-001治疗晚期胰腺癌的随机、双盲双模拟、安慰剂平行对照、多中心临床研究
[Translation] A randomized, double-blind, double-dummy, placebo-controlled, multicenter clinical study of K-001 in the treatment of advanced pancreatic cancer
在同时接受最佳支持治疗的三线及以上晚期胰腺癌患者中评价K-001治疗的有效性和安全性
[Translation] To evaluate the efficacy and safety of K-001 in patients with advanced pancreatic cancer who are receiving third-line or higher-level treatment concurrently with best supportive care
K-001治疗晚期胰腺癌的单药累积性耐受性I期临床研究
[Translation] Phase I clinical study of cumulative tolerance of K-001 as a single agent in the treatment of advanced pancreatic cancer
1、评价患者对K-001单药的不良反应和耐受程度,提供安全的剂量范围;
2、初步推算合理的剂量和给药方案;
3、初步观察疗效;
[Translation] 1. Evaluate the adverse reactions and tolerance of patients to K-001 monotherapy and provide a safe dosage range;
2. Preliminarily calculate the reasonable dosage and administration schedule;
3. Preliminarily observe the efficacy;
K-001治疗晚期肝细胞癌(HCC)的随机、双盲双模拟、阳性药平行对照、多中心临床研究
[Translation] A randomized, double-blind, double-dummy, active drug parallel-controlled, multicenter clinical study of K-001 in the treatment of advanced hepatocellular carcinoma (HCC)
观察和评价申报新药K-001治疗晚期HCC的有效性和安全性
[Translation] Observe and evaluate the efficacy and safety of the new drug K-001 in the treatment of advanced HCC
100 Clinical Results associated with Beijing Huashitianfu Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Beijing Huashitianfu Biomedical Technology Co., Ltd.
100 Deals associated with Beijing Huashitianfu Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Beijing Huashitianfu Biomedical Technology Co., Ltd.